Truc le, DO
Family Medicine · Houston, TXNPI 1093714388
Payments from drug & device makers
Across 234 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$648
- AstraZeneca$611
- Boehringer Ingelheim$420
- Amgen$413
- Johnson & Johnson$321
- AbbVie$277
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,23697%
- Education$1113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 31 | $648 |
| AstraZeneca | 35 | $611 |
| Boehringer Ingelheim | 23 | $420 |
| Amgen(2 entities) | 23 | $413 |
| Johnson & Johnson | 17 | $321 |
| AbbVie(2 entities) | 16 | $277 |
| Bayer | 21 | $267 |
| Teva Pharmaceuticals USA, Inc. | 6 | $181 |
| Abbott | 10 | $166 |
| Lilly USA, LLC | 8 | $142 |
| Globus Medical | 1 | $133 |
| Novo Nordisk | 5 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| Idorsia Pharmaceuticals US Inc | 4 | $66 |
| Kowa Pharmaceuticals America, Inc. | 2 | $41 |
| Exact Sciences | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Pfizer | 2 | $33 |
| Bristol Myers Squibb | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Novartis | 2 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $22 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Aytu Biopharma, Inc. | 1 | $21 |
| Merck | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,347 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 436 | $144,682 |
| IngrezzaValbenazine Tosylate | 26 | $103,830 |
| MounjaroTirzepatide | 66 | $75,690 |
| JardianceEmpagliflozin | 103 | $63,841 |
| OtezlaApremilast | 11 | $62,120 |
| OzempicSemaglutide | 46 | $58,741 |
| JanuviaSitagliptin Phosphate | 79 | $31,859 |
| FarxigaDapagliflozin Propanediol | 38 | $31,347 |
| TrulicityDulaglutide | 27 | $29,850 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $14,144 |
| XareltoRivaroxaban | 50 | $11,064 |
| Formoterol Fumarate | 12 | $10,143 |
| TradjentaLinagliptin | 17 | $9,094 |
| MultaqDronedarone Hcl | 22 | $8,745 |
| Potassium Chloride | 117 | $8,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $144,682436 claims |
| Lilly USA, LLCMounjaro, Trulicity | $142 | $105,54093 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $21 | $103,83026 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $420 | $78,638131 claims |
| AmgenOtezla | $413 | $62,12011 claims |
| Novo NordiskOzempic | $99 | $58,74146 claims |
| MerckJanuvia | $16 | $31,85979 claims |
| AstraZenecaFarxiga | $611 | $31,34738 claims |
| Johnson & JohnsonXarelto | $321 | $11,06450 claims |
| NovartisEntresto | $26 | $5,31411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.